. Author manuscript; available in PMC: 2021 Jul 1.

Published in final edited form as: Arthritis Care Res (Hoboken). 2020 Jun 11;72(7):1029–1037. doi: 10.1002/acr.23924

Table 4.

Association of medications with preterm delivery among women with psoriatic arthritis (N = 117) and ankylosing spondylitis (N = 129) by trimester of use in OTIS cohort 2004–2018

	Biologic DMARDs^a			Non-biologic DMARDs^a			NSAIDs^a			Corticosteroids^a
	Any^b	1T	2T	Any^b	1T	2T	Any^b	1T	2T	Any^b	1T	2T
PsA
	N = 101	N = 94	N = 72	N = 14	N = 12	N = 11	N= 20	N = 14	N = 9	N = 33	N = 26	N = 25
Preterm Delivery, n (%)	14 (13.9)	12 (12.8)	12 (16.7)	1 (7.1)	1 (8.3)	1 (9.1)	5 (25.0)	2 (14.3)	3 (33.3)	6 (18.2)	5 (19.2)	5 (20.0)
Adjusted Risk Ratio (95% CI)^c	0.92 (0.23–3.74)	0.49 (0.18–1.36)	1.89 (0.59–6.01)	0.50 (0.07–3.77)	0.55 (0.07–4.11)	0.69 (0.08–5.60)	2.34 (0.79–6.94)	0.96 (0.24–3.90)	2.73 (0.71–10.52)	1.45 (0.47–4.48)	1.58 (0.53–4.77)	1.19 (0.41–3.49)
AS
	N = 105	N = 101	N = 80	N = 10	N = 9	N = 4	N = 30	N = 26	N = 11	N = 62	N = 20	N = 28
Preterm delivery, n (%)	11 (10.5)	10 (9.9)	7 (8.8)	1 (10.0)	1 (11.1)	0 (0)	1 (3.3)	1 (3.8)	0 (0)	8 (12.9)	2 (10.0)	7 (25.0)
Adjusted Risk Ratio (95% CI)^c	1.29 (0.23–7.25)	1.03 (0.22–4.78)	0.74 (0.25–2.19)	0.92 (0.28–2.99)	0.92 (0.28–2.99)	--	0.36 (0.05–2.70)	0.45 (0.06–3.28)	--	2.22 (0.71–6.92)	0.98 (0.22–4.25)	4.41 (1.57–12.41)

Reference group for analysis is all other subjects, including all other medication use

Any use in either the 1^st or 2^nd trimester (3^rd trimester use excluded)

Multivariable adjusted risk ratio computed using Poisson regression with robust errors for: Maternal age, Race (white), SES (high), Pre-pregnancy BMI, Smoking, Parity, Preexisting medical disease (HTN, thyroid disease, diabetes, asthma), previous adverse pregnancy outcome (preeclampsia, preterm, IUGR), and disease activity defined by HAQ at intake for PsA and RAPID3 at intake for AS; DMARDs = Disease-Modifying Anti-Rheumatic Drugs; NSAIDs = Non-Steroidal Anti-Inflammatory Drugs